|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.770 EUR | +2.09% |
|
-1.98% | +3.71% |
| 06-21 | Evolus, Inc.(NasdaqGM:EOLS) added to S&P Pharmaceuticals Select Industry Index | CI |
| 05-11 | Evolus, Inc. Launches Estyme Injectable Hyaluronic Acid Gels Collection in Europe | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Cash or Net Debt
- Stock Market
- Stocks
- EOLS Stock
- EVL Stock
- Consensus Evolus, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
